Expand ASND Menu
ASND MENU

ASND Latest Press Releases

-- April 21, 2026 --

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 Globe Newswire 4:31 PM

-- April 20, 2026 --

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq Globe Newswire 8:00 AM

-- April 8, 2026 --

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq Globe Newswire 12:00 PM
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon hGH Accelerated TransCon CNP's Benefits Beyond Linear Growth in Children with Achondroplasia Globe Newswire 8:01 AM

-- April 6, 2026 --

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL (Navepegritide) in the United States Globe Newswire 4:01 PM

-- March 17, 2026 --

New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 Globe Newswire 8:30 AM

-- March 16, 2026 --

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 Globe Newswire 8:00 AM

-- March 2, 2026 --

Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference Globe Newswire 8:43 AM

-- February 27, 2026 --

FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older Globe Newswire 5:57 PM

-- February 11, 2026 --

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results Globe Newswire 4:01 PM

-- February 4, 2026 --

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 Globe Newswire 4:01 PM

-- January 9, 2026 --

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 6:01 PM

-- January 8, 2026 --

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) Globe Newswire 4:01 PM

-- January 5, 2026 --

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes